2018 American Transplant Congress
One-Year Outcomes in Patients with Advanced Liver Fibrosis or Compensated Cirrhosis from Chronic Hepatitis C Receiving Kidney Transplant Alone
Background: Hepatitis C (HCV) was difficult to treat post-kidney transplant prior to the direct acting antiviral (DAA) era. As such patients with advanced fibrosis and…2018 American Transplant Congress
Cost Effectiveness of Hepatitis C Positive Donor Kidney Transplantation for Hepatitis C Negative Recipients with Concomitant Direct-Acting Anti-Viral Therapy
Virginia Commonwealth University, Richmond.
Background: The development of direct acting antiviral (DAA) therapy for hepatitis C virus (HCV) could allow for safe and effective treatment following renal transplantation (RT).…2018 American Transplant Congress
Treatment of HCV Infection in Renal Transplant Recipients
Renal Transplant Unit, Instituto de Nefrologia Nephrology, Buenos Aires, Argentina.
HCV infection is associated to chronic hepatitis, cirrhosis, hepatic carcinoma and increased incidence of diabetes. Combination of new antiviral drugs have demonstrated utility in liver…2018 American Transplant Congress
Optimizing Outcomes with a Collaborative Approach after Kidney Transplant in Hepatitis C-Positive Recipients Receiving Hepatitis C-Positive Grafts
Piedmont Transplant Institute, Piedmont Healthcare, Atlanta, GA.
PURPOSE: To evaluate the multidisciplinary approach to HCV treatment in HCV+ kidney recipients receiving HCV+ grafts. METHODS: Single center review of treatment and outcomes in…2018 American Transplant Congress
Decision-Making, Informed Consent, and the Experiences of Recipients of Experimental HCV Positive-to-Negative Renal Transplants
Background: The safety and efficacy of transplanting HCV-infected (HCV+) donor organs into HCV-uninfected recipients (HCV D+/R-) is being studied. Recipient experiences are essential to comprehensively…2018 American Transplant Congress
Intentional Transplantation of Hepatitis C Positive Livers into Hepatitis Negative Recipients- Report of the First Case-Series in the World
Dept. of Surgery, Univ of Massachusetts, Worcester, MA.
Background: The current disparity between supply and demand of liver grafts has dramatically increased the waiting time and mortality on the waiting list. The recent…2018 American Transplant Congress
A Comparison of the Discard Rate in Hepatitis C Deceased Liver Donors between Two Eras, 2008-2013 and 2014-2017. A Single Organ Procurement Organization Experience
With the introduction of new hepatitis C medications in 2014 , there is a growing concern for an increase in the discard rate of hepatitis…2018 American Transplant Congress
Introduction of Direct Acting Antivirals for HCV: Fewer Kidney Discards but a Long Way to Go
Organ shortage remains a great challenge facing the field of kidney transplantation. Donor hepatitis C virus positivity (DHCV+) is one of the highest ranking factors…2018 American Transplant Congress
HIV, HBV, and HCV Screening with NAT and Serology in the OPO Setting
1UMass Memorial Medical Center, Worcester, MA; 2Northwestern University, Chicago, IL.
Background:In December 2014, the Organ Procurement & Transplantation Network updated policy to mandate screening with nucleic acid tests (NAT) for hepatitis C virus (HCV) in…2018 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of genotype 4 HCV has shifted to interferon free…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 28
- Next Page »